Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

AZ and Lilly to partner for ALZ drug. Hmm....I

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30067
Posted On: 09/16/2014 2:15:49 PM
Posted By: Tanis2476
AZ and Lilly to partner for ALZ drug.

Hmm....I bet they wish they had a good screening tool for the enrollment..

AstraZeneca and Eli Lilly to unite for Alzheimer’s drug challenge
By Andrew Ward, Pharmaceuticals Correspondent

AstraZeneca has struck a deal to jointly develop a treatment for Alzheimer’s disease with Eli Lilly of the US in a partnership that
promises to add momentum to industry efforts to tackle one of the biggest public health challenges facing the developed world.
Drugmakers are facing pressure from governments to step up research and development into Alzheimer’s and other forms of dementia
after years of false starts and dead ends.

AstraZeneca declared in May that it was looking for a partner to co-develop its experimental drug, AZD3293, which aims to suppress
the build up of a brain plaque that is strongly associated with Alzheimer’s.
Under Tuesday’s agreement, AstraZeneca would receive up to $500m from Eli Lilly if the drug proves successful in clinical trials, with
the two companies sharing development costs as well as potential revenues in the event of it reaching market.

In bullish forecasts issued while fending off a takeover approach from Pfizer in May, AstraZeneca said AZD3293 could generate as
much as $5bn in annual sales if trials were successful.
However, the company put the chance of this happening at just 9 per cent because of the high failure rate in Alzheimer’s research.
Only three new dementia drugs have reached market in the past 15 years and these provide only temporary relief from the condition.
The high risks involved in Alzheimer’s drug development have deterred investment, prompting David Cameron, UK prime minister, to
launch a push last year through the G8 group of leading economies to find ways of incentivising research.

Eli Lilly is one of the few big pharmaceutical companies to have remained committed to the field, together with Merck and Johnson &
Johnson of the US and Roche of Switzerland.
For AstraZeneca, the deal fits the strategy spelt out by Pascal Soriot, chief executive, to strike partnerships in non-core therapeutic
areas while sharpening its focus on cancer, diabetes, respiratory and cardiovascular disease.

Mr Soriot is under pressure from shareholders to accelerate the company’s development pipeline after setting ambitious growth targets
during its takeover battle with Pfizer.

AstraZeneca and Eli Lilly plan to move AZD3293 rapidly into advanced trials in patients in the early stages of Alzheimer’s disease, with
the US company leading clinical development while its UK partner takes responsibility for manufacturing.

The drug is one of several so-called BACE inhibitors at different stages of development, which have become the main hope of a
breakthrough in dementia.

“Alzheimer’s disease is one of the biggest challenges facing medical science today and BACE inhibitors have the potential to target one
of the key drivers of disease progression,” said Mene Pangalos, head of innovative medicines and early development at AstraZeneca.
Dementia, of which Alzheimer’s is the most common form, already affects 44m people worldwide and this is set to reach 135m by 2050
as populations age, according to Alzheimer’s Disease International, a non-profit group.


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us